Company profile
4D Molecular Therapeutics, Inc.
NASDAQ: FDMT · Healthcare · Biotechnology
#367 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
58CFH 61DQ 51GM 65SS 58
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), 3-yr revenue growth · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$88.2M
Rev growth YoY (TTM)
+383560.9%
Net income (FY)
-$140.1M
Employees
196
as of 2026-08-11
Market cap
$582.4M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$85.2M$85.2M2025
Net income-$140.1M-$140.1M2025
Operating income-$159.5M-$159.5M2025
Total assets$566.7M$566.7M2025
Liabilities$61.0M$61.0M2025
Equity$505.7M$505.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration And License Revenue100%
By geography
JAPAN100%
UNITED STATES0%
The read
What is 4D Molecular Therapeutics, Inc.’s revenue?
4D Molecular Therapeutics, Inc. booked $85.2M in FY2025 revenue, growing 230195% year over year — faster than 100% of Healthcare companies we track, at a -164.4% net margin.
Peers · Healthcare
4Front Ventures Corp.——Standard BioTools Inc.61CDelcath Systems, Inc.72BARS Pharmaceuticals, Inc.41DNurix Therapeutics, Inc.53DIRadimed Corporation86ANeighbors
Alameda →Key facts
CEODavid H. Kirn
SectorHealthcare
IndustryBiotechnology
HeadquartersEmeryVille, CA
ExchangeNASDAQ: FDMT
Employees196
IPO date2020-12-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.